Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 | Industry Shares, Size, Trend, Analysis, and Forecasts to 2019 Report Available Online by Researchmoz.us

ResearchMoz.us include new market research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports. Full Report @ http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
ResearchMoz

ResearchMOZ

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019

Albany, NewYork (PRWEB) February 06, 2014

GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth”. The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019.

Read Complete Report With TOC @ http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html

This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.

Cystic Fibrosis Transmembrane conductance Regulators (CFTR) modulators are the first type of CF therapy to treat the root cause of the disease rather than the symptoms, and as a result, they offer patients improved relief and quality of life. Kalydeco (ivacaftor), which has been marketed since 2012, was the first CFTR modulator to reach the market, and despite only treating a small proportion of the CF population, it had a large impact on the value of the market. This effect will be repeated on a larger scale when lumacaftor and Ataluren (PTC124) enter the market, as these treatments can be used for a much larger proportion of the CF population. Vertex Pharmaceuticals Inc. are the developers of Kalydeco, lumacaftor and other early phase CFTR modulators, and are therefore expected to play a key role in the development of the future CF market.

Browse All Countrywise Report @ http://www.researchmoz.us/country.html

Scope

A disease introduction, which defines the disease, including symptoms, diagnosis and treatment.
An analysis of the CF marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of CF treatment.
A detailed analysis of the CF pipeline, detailing, among other parameters, drug distribution by phase, molecule type and mechanism of action. The CF clinical trial landscape is then analyzed, with a particular emphasis on failure rates across different trial phases as well as the trends in clinical trial size and duration. This section also includes profiles and single product forecasts for the most promising pipeline drugs.
An epidemiological forecast of the major CF markets. The projected values include total and treated populations.
An in-depth forecasting model for the CF market, which considers the current marketed therapies, in addition to the potential entry of new products into the market. The model consists of a projected outcome, with high and low variance results, depending on the potential performance of pipeline therapies.
Analysis of strategic consolidations within the CF indication, including co-development and licensing agreements.
An overview of the drivers and barriers for the CF market is also included

All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html

Reasons to Buy

Understand the CF pipeline and the clinical needs it is addressing. In particular, the importance and benefits of CFTR modulators are highlighted and compared with symptomatic treatments.
Develop their knowledge of key products that may enter the market before 2019. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the CF treatment plan and what competition they face.
Assess the risk associated with CF clinical trials compared with both industry and therapy area averages. In addition, in order to understand the trends in both trial size and duration according to mechanism of action or molecule type.
Identify patterns of growth in the CF market over the forecast period and understand the underlying causes, as well as observing the contributions made by each major market to this growth.

Related Report

Global Proton Therapy Market

Proton therapy (http://www.researchmoz.us/global-proton-therapy-market-trends-and-opportunities-2013-2018-report.html) or proton beam therapy is a highly precise method of radiotherapy. The treatment is suitable for all patients regardless of age and as proton-therapy technology is continuously advancing, features such as rotational gantries, higher energies and larger fields have expanded the treatment's application to potentially any site in the body. IBA is the world leader and market pioneer of proton therapy.Globally the penetration of proton therapy centers is highest in North America, mainly in the US, followed by Europe and Asia.

Systemic Psoriasis Therapeutics in Major Developed Markets to 2020

GBI Research has released its pharma report (http://www.researchmoz.us/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-description-report.html) “Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth”. The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period.

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948            
Email: sales(at)researchmoz(dot)us
http://www.researchmoz.us/
Blog: http://industryresearchnews.blogspot.com